SCHEMBL836384

SCHEMBL836384

Cc1cc(C#Cc2cncc(C(=O)N=S(C)(=O)c3ccc(Cl)cc3)c2)ccc1F

nearest known ligand 0.49

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
KDR P35968 16/20 0.49
PDGFRB P09619 10/20 0.49
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
GRM5 P41594 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL833670 0.93 KDR (0.54) KDRPDGFRBPTGS2GRM5
SCHEMBL834582 0.92 KDR (0.49) KDRPDGFRBPTGDR2GRM5
SCHEMBL835775 0.91 KDR (0.52) KDRPDGFRBGRM5
SCHEMBL834661 0.91 KDR (0.50) KDRPDGFRBGRM5
SCHEMBL836534 0.90 KDR (0.52) KDRPDGFRB
SCHEMBL835541 0.90 KDR (0.47) KDRPDGFRBPTGS1PTGS2PTGDR2
SCHEMBL834808 0.89 KDR (0.47) KDRPDGFRB
SCHEMBL835477 0.89 KDR (0.52) KDRPDGFRBGRM5
SCHEMBL836023 0.88 KDR (0.52) KDRPDGFRB
SCHEMBL835000 0.88 KDR (0.52) KDRPDGFRBPTGS1PTGS2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099757-B1 SULFOXIMINES AS KINASE INHIBITORS ALLERGAN INC (US) 2014-06-25 EP disclosed
US-8383825-B2 Kinase inhibitors ALLERGAN, INC. (US) 2013-02-26 US disclosed
US-20120207810-A1 Kinase Inhibitors SPADA LON T (US) 2012-08-16 US disclosed
US-8143410-B2 Kinase inhibitors ALLERGAN, INC. (US) 2012-03-27 US disclosed
US-20110263611-A1 Kinase Inhibitors ALLERGAN, INC. 2011-10-27 US disclosed
US-7915443-B2 Sulfoximines as kinase inhibitors ALLERGAN, INC. (US) 2011-03-29 US disclosed
US-20090196906-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-06 US disclosed
US-20090099181-A1 SULFOXIMINES AS KINASE INHIBITORS ALLERGAN, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263611-A1 Kinase Inhibitors PTK2, MAP3K6, MAP3K20 KDR 51/4885PDGFRB 368/4885PTGS1 635/4885
US-20120207810-A1 Kinase Inhibitors PTK2, MAP3K6, MAP3K20 KDR 51/4885PDGFRB 368/4885PTGS1 635/4885
US-20090196906-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 KDR 51/4885PDGFRB 368/4885PTGS1 635/4885
US-20090099181-A1 SULFOXIMINES AS KINASE INHIBITORS SRC, PTK2B, TYRO3 KDR 321/4885PDGFRB 409/4885PTGS1 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.